ROCKVILLE, Md. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Application

ROCKVILLE, Md. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an

ROCKVILLE, Md. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an

Total revenue of $126.7 million , including net product sales of $89.7 million for Trokendi XR®, $23.7 million for Oxtellar XR®, and $10.6 million for the acquired Parkinson’s disease (PD) products Operating earnings of $45.5 million Completed acquisition of CNS portfolio of US WorldMeds on June 9,

Second quarter total revenue is estimated to be $126.7 million , a 21% increase over 2019 Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million , an 11% increase over 2019 Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 Management to host a

ROCKVILLE, Md. , June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex

Creates leading CNS portfolio with five marketed products, two product candidates in late-stage development, and robust pipeline ROCKVILLE, Md. , June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing

ROCKVILLE, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an

ROCKVILLE, Md. , May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that on May 14, 2020 the Company received

First quarter total revenue of $95.0 million , an 11% increase over 2019 First quarter net product sales of $92.5 million , an 11% increase over 2019 First quarter operating earnings of $29.0 million , a 14% increase over 2019 On track for launch of SPN-812 at the end of 2020, pending FDA approval.